Literature DB >> 10856724

The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York.

J G Cleland1, K Swedberg, A Cohen-Solal, J Cosin-Aguilar, R Dietz, F Follath, A Gavazzi, R Hobbs, J Korewicki, H C Madeira, I Preda, W H van Gilst, J Widimsky, V Mareev, J Mason, N Freemantle, J Eastaugh.   

Abstract

BACKGROUND: The EUROHEART programme is a rolling programme of cardiovascular surveys among the member nations of the European Society of Cardiology (ESC). These surveys will provide information on the nature of cardiovascular disease and its management. This manuscript describes a survey into the nature and management of heart failure. AIMS: The EuroHeart Failure survey aims to describe the quality of hospital care, diagnostic and therapeutic, for patients with suspected or confirmed heart failure in ESC member countries. Patients will be interviewed subsequent to hospital discharge to assess their understanding of their condition, side effects from and their compliance with therapy and their satisfaction with the management for heart failure. The quality of management will be judged against the recommendations contained in the ESC guidelines on diagnosis and treatment of heart failure. Outcome will be further assessed by repeat interviews in 6-12 months time. A further survey of heart failure in 2001/2002 is also planned.
METHODS: A prospective survey of all deaths and discharges from medical (cardiology, internal medicine and geriatric medicine) and cardiac surgical wards to identify patients with heart failure, suspected or confirmed. Approximately 70 hospital clusters, comprising two to six hospitals in each cluster, in 24 member countries of the ESC are conducting the study. At the time of writing, approximately 30000 deaths and discharges have been screened and approximately 4000 patients have been enrolled.
CONCLUSIONS: The EuroHeart Survey will allow actual practice to be compared to ESC guidelines on the diagnosis and treatment of heart failure. The surveys and guidelines should prove mutually informative. The main EuroHeart Failure project will be completed by late 2000. However, new centres volunteering to participate in the study (contact corresponding author) may be accepted providing they have the necessary research personnel and provided funding can be agreed for statistical support and administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856724     DOI: 10.1016/s1388-9842(00)00081-7

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  28 in total

Review 1.  Contemporary management of heart failure in clinical practice.

Authors:  J G F Cleland
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 2.  Functional links between transcription, DNA repair and apoptosis.

Authors:  P Berardi; M Russell; A El-Osta; K Riabowol
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

3.  Coronary sinus dilatation is associated with left ventricular systolic dysfunction and poor functional status in subjects with chronic heart failure.

Authors:  Murat Yuce; Vedat Davutoglu; Sema Yavuz; Ibrahim Sari; Nese Kizilkan; Suleyman Ercan; Murat Akcay; Cayan Akkoyun; Adnan Dogan; Hayri Alici; Murat Cavdar; Hasan Buyukarslan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

4.  Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey.

Authors:  P Velavan; N K Khan; A S Rigby; K Goode; M Komajda; F Follath; K Swedberg; H Madeira; A L Clark; J G F Cleland
Journal:  Heart       Date:  2006-02       Impact factor: 5.994

5.  Telemonitoring for heart failure: the only feasible option for good universal care?

Authors:  John G F Cleland; Christian Lewinter; Kevin M Goode
Journal:  Eur J Heart Fail       Date:  2009-03       Impact factor: 15.534

6.  Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-06-24       Impact factor: 2.778

7.  [New options in the treatment of acute heart failure].

Authors:  A Link; M Böhm
Journal:  Internist (Berl)       Date:  2014-06       Impact factor: 0.743

Review 8.  Epidemiology and importance of renal dysfunction in heart failure patients.

Authors:  Gregory Giamouzis; Andreas P Kalogeropoulos; Javed Butler; Georgios Karayannis; Vasiliki V Georgiopoulou; John Skoularigis; Filippos Triposkiadis
Journal:  Curr Heart Fail Rep       Date:  2013-12

9.  Outcome of heart failure with preserved ejection fraction: a multicentre spanish registry.

Authors:  Juan C Castillo; Manuel P Anguita; Manuel Jiménez
Journal:  Curr Cardiol Rev       Date:  2009-11

Review 10.  Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.

Authors:  Donatella Del Sindaco; Maria Denitza Tinti; Luca Monzo; Giovanni Pulignano
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.